Emmaus rises as blood disorder drug powers Q2 sales surge

Emmaus Life Sciences

12/08/2019 16:49

** Shares of drug developer Emmaus Life Sciences  EMMA.O 
rise 14% to $4.3 
    ** Co, formerly MYnd Analytics Inc, says Q2 revenues rose
128% to $5.9 mln, driven by demand for its sickle cell disease
treatment Endari  urn:newsml:reuters.com:*:nPn6C16BZa
    ** Posts Q2 loss of $0.6 mln vs $2.8 mln last year
    ** In June, EMMA said it received a delisting notice from
Nasdaq following its merger with MYnd Analytics  urn:newsml:reuters.com:*:nFWN24N0VW 
    ** Co says it is reviewing options related to maintaining
listing on Nasdaq 
    ** Up to Friday's close, EMMA had fallen ~14% this year

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))